Federal contract award
75F40123C00142
IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.1M |
| Current contract value | $1.1M |
| Potential contract value / ceiling | $1.1M |
| Start date | Sep 22, 2023 |
| Current end date | Sep 29, 2027 |
| Potential end date | Sep 29, 2027 |
| Latest award activity | May 21, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 21, 2026 | P00005 | $0 | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
| Sep 10, 2025 | P00004 | $446.4K | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
| Jul 22, 2024 | P00003 | $408.6K | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
| Feb 2, 2024 | P00002 | $0 | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
| Jan 23, 2024 | P00001 | $0 | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
| Sep 22, 2023 | 0 | $248.9K | IMPACT OF API CQAS ON IN SITU FORMING IMPLANTS AND UNDERSTANDING IN VITRO AND IN VIVO PERFORMANCE DIFFERENCES |
Estimated positioning window
Nov 1, 2026 – Mar 29, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-29 (332 days from calculation)
- +35 points
- 15 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-05-21
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | May 18, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | May 18, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 17, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 17, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 3, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 3, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 17, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 17, 2022 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 14, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 14, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.